Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

BACKGROUND: The ongoing COVID-19 pandemic warrants accelerated efforts to test vaccine candidates. We aimed to assess the safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidate, BBIBP-CorV, in humans. METHODS: We did a randomised, d...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Lancet Infect Dis
Main Authors: Xia, Shengli, Zhang, Yuntao, Wang, Yanxia, Wang, Hui, Yang, Yunkai, Gao, George Fu, Tan, Wenjie, Wu, Guizhen, Xu, Miao, Lou, Zhiyong, Huang, Weijin, Xu, Wenbo, Huang, Baoying, Wang, Huijuan, Wang, Wei, Zhang, Wei, Li, Na, Xie, Zhiqiang, Ding, Ling, You, Wangyang, Zhao, Yuxiu, Yang, Xuqin, Liu, Yang, Wang, Qian, Huang, Lili, Yang, Yongli, Xu, Guangxue, Luo, Bojian, Wang, Wenling, Liu, Peipei, Guo, Wanshen, Yang, Xiaoming
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier Ltd. 2021
Assuntos:
Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7561304/
https://ncbi.nlm.nih.gov/pubmed/33069281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(20)30831-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares